Literature DB >> 802650

Some haemodynamic effects of compound AH 5158 compared with propranolol, propranolol plus hydrallazine, and diazoxide: the use of AH 5158 in the treatment of hypertension.

B N Prichard, F O Thompson, A J Boakes, A M Joekes.   

Abstract

1. Intravenous administration of compound AH 5158, which possesses alpha- and beta-adrenergic receptor-blocking properties, produces haemodynamic effects similar to those seen from the combined effects of propranolol and hydrallazine. 2. Chronic oral administration has demonstrated that compound AH 5158 is an effective hypotensive agent capable of controlling the blood pressure in patients previously requiring large doses of drugs such as methyldopa. Some postural and exercise hypotension may be seen with larger doses.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 802650     DOI: 10.1042/cs048097s

Source DB:  PubMed          Journal:  Clin Sci Mol Med Suppl        ISSN: 0144-4107


  21 in total

1.  Assessment of alpha- and beta-adrenoceptor blocking actions of labetalol.

Authors:  D A Richards; J Tuckman; B N Prichard
Journal:  Br J Clin Pharmacol       Date:  1976-10       Impact factor: 4.335

Review 2.  Properties of labetalol, a combined alpha- and beta-blocking agent, relevant to the treatment of myocardial ischemia.

Authors:  W H Frishman
Journal:  Cardiovasc Drugs Ther       Date:  1988-09       Impact factor: 3.727

Review 3.  The second Lilly Prize Lecture, University of Newcastle, July 1977. beta-Adrenergic receptor blockade in hypertension, past, present and future.

Authors:  B N Prichard
Journal:  Br J Clin Pharmacol       Date:  1978-05       Impact factor: 4.335

Review 4.  Labetalol: a review of its pharmacology and therapeutic use in hypertension.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1978-04       Impact factor: 9.546

5.  Improved deep controlled hypotension in aneurysmal surgery.

Authors:  V Lüben; G Hempelmann
Journal:  Acta Neurochir (Wien)       Date:  1982       Impact factor: 2.216

Review 6.  Comparison of labetalol with other anti-hypertensive drugs.

Authors:  B N Prichard; D A Richards
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

7.  The use of labetalol in Japan: results of multicentre clinical trials.

Authors:  T Takeda; Y Kaneko; T Omae; K Yoshinaga; Y Masuyama; T Nukada; R Shigiya
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

Review 8.  Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease.

Authors:  K L Goa; P Benfield; E M Sorkin
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

9.  Intravenous labetalol in hypertensive patients given by fast and slow injection.

Authors:  R M Pearson; C W Havard
Journal:  Br J Clin Pharmacol       Date:  1978-05       Impact factor: 4.335

10.  The acute and chronic hypotensive effect of labetalol and the relationship with pretreatment plasma noradrenaline levels.

Authors:  E Agabiti-Rosei; C L Alicandri; M Beschi; M Castellano; R Fariello; E Montini; M L Muiesan; G Romanelli; G Muiesan
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.